ArticleFrontiers in oncology2022

Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis.

Wai-Nga Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.